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Abstract 
Background: Alpha-thalassemia syndrome includes a group of hereditary anemia in which expression of alpha 
globin chains is decreased or absent. Impaired RBC in patients with thalassemia causes vessel involvement and 
endothelial cell vessel disturbance. Vascular Endothelial Growth Factor (VEGF) is the most important regulator for 
endothelial cell proliferation. So, the aim of this study is to compare the serum VEGF levels in patients with alpha 
thalassemia and normal control group.  
Materials and Methods: This case-control study was conducted on 17 patients with alpha thalassemia and 40 
healthy people. Serum VEGF levels were measured by enzyme-linked immune sorbent assay (ELISA) kit. Then 
statistical analysis of results were performed using SPSS 16, value of P <0.05 was considered statistically significant.  
Results: Mean serum VEGF levels in case and control groups were 2294.19±1552.39 and  598.09±988.17pg/ml, 
respectively. Serum VEGF levels were higher in patients with alpha thalassemia  (P <0.01). There was no significant 
correlation between serum VEGF levels and Hemoglobin. (P= 0.73).  
Conclusion: Our study revealed that patients with alpha thalassemia have elevated levels of serum VEGF than 
normal control group. Further studies with larger sample size are recommended to confirm these observations. 
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Thalassemia is the most common monogenic 
disorder in the Worldwide (1). Alpha-thalassemia 
syndrome includes a group of hereditary anemia in 
which expression of alpha globin chains are decreased 
or absent (2). Alpha thalassemia is heterogeneous in 
the molecular levels which is the result of point 
mutations , small base insertions or deletions that 
affect the region encoding α1 and α2 genes on  
chromosome 16 (3). All four α-globin alleles are 
deleted or inactivated in Hemoglobin Bart syndrome. 
Deletion or dysfunction of three alleles results in HbH 
disease. Minor or trait  alpha-thalassemia results from 
mutation in two alleles, and α+-thalassemia occurs 
when one allele has been mutated (4).  
Impaired RBCs  in patients with thalassemia 
result in vessel involvement and endothelial cell 
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vessel disturbance (5). In some cultural studies, low 
growth and disturbance of endothelial cell vessels in 
exposed to thalassemia serum were seen (6).  
Angiogenesis is an important process in 
development and growth of new blood vessels. In this 
process, endothelial cell proliferation forms vascular 
networks for reestablishment of blood flow in injured 
tissues (7). Vascular endothelial growth factor 
(VEGF) is the most important regulator for this 
process (8). VEGF is a critical regulator of 
hemangioblastic differentiation and blood vessels 
formation (6). Tissue hypoxia is a main stimulus for 
the up-regulation of VEGF, so patients with anemia  
have elevated  serum levels of VEGF. It seems that 
anemia might impact on the progression of 
angiogenesis (9). 
The role of angiogenesis in several types of 
anemia was determined, but studies about its 
character in alpha   thalassemia  were too low. The 
aim of this study , is to compare  the serum levels of 
VEGF as a marker of angiogenesis in patients with 
alpha thalassemia with normal control group. 
Methods 
This case-control study was carried out in 
Zafar Thalassemia Clinic, Tehran, during 2015-2016. 
Study population was consisted of 17 patients with 
alpha thalassemia and 40 healthy controls. Case and 
control groups were matched regarding the gender 
and age. Patients with other hemoglobinopathies, 
malignancies or other causes of anemia were 
excluded from the study. This study was approved in 
Ethical committee at Tehran University of Medical 
Sciences (TUMS) and 
 All of our participants in both groups had 
completed consent form. 
A questionnaire consisted of demographic 
characterization such as gender and age was filled for 
every patients. Results of some laboratory and 
molecular tests were extracted from their clinical 
records. 
Diagnosis of alpha thalassemia was based on 
laboratory test, peripheral blood smear, molecular test 
and clinical manifestations. Blood samples were 
collected with EDTA anticoagulant and Cell Blood 
Count (CBC) test was done with Sysmex machine, 
KX21N (Sysmex Corporation Kobe, Japan). The 
samples were centrifuged for 10 minutes then sera 
were separated and stored at -70°C. Eventually, serum 
VEGF levels were measured by enzyme-linked 
immunosorbent assay ( ELISA kit) Booster Biological 
Technology Co, Ltd). The detection limit of the serum 
VEGF assay was 9 pg/ml, the intra-assay precision 
was ≤ 6 % and the inter-assay precision was ≤10%. 
To adjust the serum VEGF level with platelet count 
and exclude the effect of the platelet count, serum 
VEGF (pg/ml) / platelet count (×103/μL) was 
calculated. 
Statistical analysis of results was performed 
using SPSS software version 16. Quantitative 
variables were expressed as mean and standard 
deviation (mean±SD). Qualitative variables were 
expressed as count and percentage. Student t- test or 
non-parametric equivalent Mann-Whitney U test was 
used for comparison between means of two groups. 
The Pearson correlation coefficient test was used to 
test the significant correlations for quantitative 
parameters. A value of P<0.05 was considered 
statistically significant. 
Results 
Case group was consisted of 17 patients with 
alpha thalassemia of which 6 (35.3%) were male and 
11(67.4 %) were female. Frequency of the different 
types of alpha thalassemia syndrome in our patients as 
follows: 2(11.7%) silent carrier, 10 (58.82%) alpha 
thalassemia trait and 5(29.41%) Hb H disease. Their 
mean age was 37.06±3.1. A total of 40 healthy 
peoples as control group were enrolled in the study, 
18(40.91 %) of them were male and 26 (50.09%) 
were female. The mean age of the control group was 
25.73 ±5.04. 
Serum VEGF levels were higher in the case 
group.  
Because of the low number of patients, 
Shapiro-Wilk test was used to assess the normality of 
the data which showed non-normal distribution. 
Comparison of  serum VEGF levels between case and 
control groups by Mann-Whitney U test revealed 
significant differences between two groups. 
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The mean range of Hemoglobin  in patients 
with  alpha- thalassemia was 11.41±2.2 and there was 
not any statistically significant correlation between 
serum VEGF levels with Hemoglobin. (P= 0.73) 
There wasn’t correlation between age and 
gender with serum VEGF levels ( P=0.86, P=0.43). 
Statistical analysis showed no significant 
association between serum VEGF levels and number 
of deletion mutation. (P = 0.63) 
Discussion 
Vascular endothelial growth factor (VEGF) is a 
key regulator of physiological angiogenesis and plays 
an important role during development of the vascular 
system, wound healing, menstrual cycle, etc. It has 
also been implicated in pathological angiogenesis 
associated with tumors and other conditions (10) 
Inhibition of angiogenesis in these situations can 
alleviate symptoms of disease (11). VEGF is 
produced in response to tissue hypoxia in anemia and 
some tumors (12). Continuance of hypoxic state leads 
to high expression of Hypoxia Induced Factor (HIF) 
which is the main gene to balance oxygen by some 
pathways like angiogenesis (13). 
Enhancement of VEGF level has been 
investigated in different kinds of anemia. However, 
its role as a marker of angiogenesis has not been 
enough assayed in alpha thalassemia.Our study 
showed that serum VEGF levels were significantly 
higher in patients with alpha thalassemia than control 
group that it was similar to Butthep and et al study. 
They found that serum VEGF level increase in 
patients with alpha and beta thalassemia (5).  
Also, we were not observed significant 
correlation between serum VEGF levels and 
hemoglobin ,that it seems probably due to most 
patients were mild alpha thalassemia, this finding  
similar to Olgar and et al study ,in which they also 
showed no significant correlation between VEGF 
levels and Hemoglobin (14). We found no significant 
correlation between serum VEGF levels and patients´ 
age that was contrast to shitrit and et al study (6). One 
of our big limitation in this study, was low sample 
size, so further studies with larger population is 
recommended to confirm these observations. 
Conclusions 
Our study showed that patients with alpha 
thalassemia have elevated levels of serum VEGF than 
normal control group. Further studies with larger 
sample size are recommended to confirm these 
observations. 
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